CJC-1295 DAC (5 mg) & Ipamorelin (5 mg) (Stack)
Combination protocol for CJC-1295 DAC (5 mg) and Ipamorelin (5 mg). The 5 mg CJC vial provides 2.5 standard doses (1 mg/week), reducing the number of vials long-term.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
CJC-1295 DAC stimulates pituitary GH via the GHRH receptor with a half-life of 6–8 days due to albumin binding. Ipamorelin activates the GHSR for rapid GH pulses without affecting ACTH/cortisol. The combination synergistically enhances endogenous GH.
Quick Start
- CJC-1295 DAC: Add 2.0 mL BAC water → 2.5 mg/mL; inject 1×/week.
- Ipamorelin: Add 3.0 mL BAC water → 1.67 mg/mL; inject 1×/day.
- Storage: Lyophilized: ≤ −15 °C; reconstituted: 2–8 °C, within 3–4 weeks.
Stacking Schedule — Standard Approach
Route: Subcutaneous | Frequency: CJC-1295 DAC: 1×/week | Ipamorelin: 1×/day
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | CJC: 1000 mcg (1 mg) weekly | 40 units (0.40 mL) | Ipam: 6 units/day |
| Weeks 3–4 | CJC: 1000 mcg (1 mg) weekly | 40 units (0.40 mL) | Ipam: 9 units/day |
| Weeks 5–12 | CJC: 1000 mcg (1 mg) weekly | 40 units (0.40 mL) | Ipam: 12 units/day |
At 2.5 mg/mL, each 5 mg vial provides 2.5 standard doses (1 mg). Administer CJC on a consistent day each week; administer Ipamorelin before bedtime.
Reconstitution Steps
Dilution Selection
Peptides come in 3 mL, 5 mL or 10 mL vials. If your vial is smaller, the water amount adjusts automatically.
CJC-1295 DAC (5 mg)
Ipamorelin (5 mg)
⚠️ Units change depending on BAC water — always verify before administration. Based on
- CJC-1295 DAC: Withdraw 2.0 mL BAC water → 2.5 mg/mL.
- Ipamorelin: Withdraw 3.0 mL BAC water → 1.67 mg/mL.
- Inject slowly down the side of the vial; swirl gently.
- Date the vial; refrigerate at 2–8 °C.
Protocol Overview
- Objective: Enhance GH/IGF-1 via GHRH + ghrelin pathways.
- Schedule: CJC 1×/week + Ipamorelin 1×/day for 8–16 weeks.
- Advantage: Fewer CJC vials compared to the 2 mg version.
Dosing Protocol
- CJC-1295 DAC: 1 mg (40 units) subcutaneously 1×/week.
- Ipamorelin: 100 mcg (6 units) → 150 mcg (wk 3–4) → 200 mcg (wk 5+).
- Timing: Ipamorelin before bedtime.
- Cycle: 8–16 weeks.
- Break between cycles: After the cycle, a washout period of 4–8 weeks is recommended. The CJC-1295 DAC + Ipamorelin combination strongly stimulates the GH axis — the washout period helps prevent tolerance.
Washout & Cycle Restart
When can I restart?
After the cycle, a washout period of 4–8 weeks is recommended. The CJC-1295 DAC + Ipamorelin combination strongly stimulates the GH axis — the washout period helps prevent tolerance.
Minimum wait period: 4 weeks
Storage Instructions
- Lyophilized: ≤ −15 °C.
- Reconstituted: 2–8 °C; use within 3–4 weeks.
Important Notes
- Do not mix CJC + Ipamorelin in the same vial.
Potential Benefits & Side Effects
Potential Benefits:
- Improved body composition.
- Sustained increase in GH/IGF-1 (6–11 days/CJC dose).
- Ipamorelin selectivity.
- Fewer vials long-term.
Potential Side Effects:
- Water retention, mild headache.
- Transient numbness/tingling.
- Injection site reactions.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical risk (prolonged GH elevation)
The DAC variant provides continuous GH elevation for 7–10 days. Theoretical concern for IGF-1-related oncogenesis.
📄 J Clin Endocrinol Metab 2006Fluid retention & edema
Prolonged GH elevation can cause fluid retention, arthralgia, and carpal tunnel syndrome.
📄 J Clin Endocrinol Metab 2006Theoretical risk (GH/IGF-1 elevation)
As a GHS, increases GH. Theoretical risk for pre-existing neoplasms due to IGF-1 elevation. No clinical signal in short-term studies.
📄 Growth Horm IGF Res 2008References
- J Clin Endocrinol Metab — CJC-1295: Prolonged GH/IGF-1 stimulation
View Source - Eur J Endocrinol — Ipamorelin: a selective GH secretagogue
View Source - Endocrine Reviews — GH secretagogues: mechanisms of action
View Source - Transl Androl Urol (PMC) — GH secretagogues on body composition
View Source
Recommended Supplements
L-Arginine + L-Ornithine
ZMA (Zinc + Magnesium + B6)
🧬 General Wellness
Multivitamin (High-Quality)
Magnesium Glycinate
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Probiotics (Multi-Strain)
Electrolytes (Na, K, Mg)
Liver Support (NAC / Milk Thistle)
External Sources & Regulatory Status
Regulatory Approvals
Postoperative ileus
Phase II (development discontinued)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →